Bio Medica Laboratories IPO - Company Analysis
Bio Medica Laboratories IPO, under the SME IPO category, is a book-built issue of Rs. 52.43 Cr by Bio Medica Laboratories Limited, which specialises in developing pharmaceutical parenteral formulations, including a variety of ethical, generic, and over-the-counter (OTC) pharmaceuticals in injectable liquid and dry powder forms.der injectables. These injectables meet the requirements of both human and veterinary healthcare and are offered in single-dose and multi-dose versions.
Portfolio of products:
- There are 58 products available in the area of liquid injectables.
- There are 15 items in the category of dry powder injectables.
Bio Medica Laboratories IPO Details
The Bio Medica Laboratories IPO date of opening is 21 May 2026, its initial public offering will end on 25 May, IPO allotment on May 26 and refund initiation on May 27, 2026.
The Rs. 52.43 crore new SME IPO comprises a combination of fresh issue of 0.34 crore shares (Rs. 47.19 Cr) and offer for sale of 0.04 crore shares (Rs. 5.24 Cr).
The Bio Medica Laboratories IPO listing date (expected) might be Friday, May 29, 2026, and listing at the NSE and SME.
The Bio Medica Laboratories IPO price band is Rs. 132 to Rs. 139.
IPO Timetable (Tentative)
|
Events |
Date |
|
IPO Opening Date |
May 21, 2026 |
|
IPO Closing Date |
May 25, 2026 |
|
IPO Allotment Date |
May 26, 2026 |
|
Refund Initiation |
May 27, 2026 |
|
IPO Listing Date |
May 29, 2026 |
Click to open demat account and apply for the IPO.
Company Financials
(Amount in Cr)
|
Particulars |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
Assets |
39.12 |
19.53 |
17.57 |
|
Total Income |
38.33 |
15.34 |
16.25 |
|
Profit After Tax |
9.79 |
2.50 |
0.33 |
|
EBITDA |
15.21 |
5.63 |
1.70 |
|
Net Worth |
14.73 |
4.94 |
2.44 |
|
Reserves and Surplus |
5.55 |
4.84 |
2.34 |
|
Total Borrowing |
15.01 |
10.49 |
9.61 |
Cash Flows
(Amount in lac)
|
Net Cash Flow |
31 Mar 2025 |
31 Mar 2024 |
31 Mar 2023 |
|
Net Cash Flow Operating Activities |
(367.17) |
162.41 |
229.31 |
|
Net Cash Flow Investing Activities |
33.88 |
(153.75) |
(168.97) |
|
Net Cash Flow Financing Activities |
332.94 |
(8.25) |
(212.53) |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The company desires to use the Net Proceeds from the Issue to fulfill its following goals:
- Repayment of loan. ~ Rs. 6.50 Cr.
- Enhancement of its existing production capabilities by setting up of a new manufacturing facility at the existing premises. ~ Rs. 28.50 Cr.
- General Corporate Purposes.
Listed Peers of Bio Medica Laboratories Ltd.
|
Companies |
Face Value (Rs.) |
EPS |
PE Ratio |
|
Zenotech Laboratories Limited |
10.00 |
0.92 |
- |
|
Shukra Pharmaceuticals Limited |
1.00 |
0.22 |
47.57 |
Valuation
|
KPI |
Value (Mar 31, 2025) |
|
ROE |
99.59% |
|
ROCE |
48.20% |
|
RoNW |
1.02 |
|
PAT Margin |
99.59% |
|
EBITDA Margin |
25.64% |
|
Price to Book Value |
39.83% |
Evaluation of P/E Ratio
Considering the period ended on FY 2025 with an EPS of Rs. 10.67 from the last year, the resulting P/E ratio is 13.03x.
Explore the Amba Auto Sales & Services IPO.
IPO's Strengths
- Multi-product capability and diversified product portfolio.
- Experienced promoters, management and employees.
- Quality assurance.
- Established client relationship.
IPO's Weaknesses
- Regulatory compliance risk.
- Customer concentration risk.
- Quality control and manufacturing risk.
Bio Medica Laboratories IPO GMP (Grey Market Premium)
Bio Medica Laboratories IPO GMP today is Rs. 0 as of 19 May 2026, while writing this information. A price band set at Rs. 139 suggests that the estimated listing price of the IPO could be around Rs. 139, indicating a gain/loss of 0%.
Bio Medica Laboratories IPO Summary
|
IPO Opening & Closing Date |
21 May, 2026 to 25 May, 2026 |
|
Face Value |
Rs. 10 per Share |
|
Issue Price |
Rs. 132 to Rs. 139 per Share. |
|
Lot Size |
1000 Shares |
|
Issue Size |
37,72,000 Shares (Rs. 52 Cr) |
|
Offer for Sale |
3,77,000 Shares (Rs. 5 Cr) |
|
Fresh Issue |
32,06,000 Shares (Rs. 45 Cr) |
|
Listing at |
NSE, SME |
|
Issue Type |
Bookbuild issue IPO |
|
Registrar |
Skyline Financial Services Pvt. Ltd. |
IPO Lot Details
Retail investors can invest in a minimum and maximum of 2 Lots (2000 Shares) for Rs. 2,78,000, and in multiples thereof, while HNI investors can invest in a minimum of 3 Lots (3000 Shares) for Rs. 4,17,000.
|
Minimum Lot Investment (Retail) |
2 Lots |
|
Maximum Lot Investment (Retail) |
2 Lots |
|
HNI (Min) |
3 Lots |
Bio Medica Laboratories IPO Allotment Status
To check the Bio Medica Laboratories IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Bio Medica Laboratories Ltd.
- Mr. Mukesh Mehta
- Mr. Pradeep Mehta
|
Pre-Issue Promoter Shareholding |
99.99% |
|
Post-Issue Promoter Shareholding |
- |
IPO Lead Managers
- Narnolia Financial Services Ltd.
Dividend Policy
The company has not paid a dividend in any financial year.
Conclusion
Bio Medica Laboratories IPO shows strong revenue and profit growth, high ROE, and expansion plans through a new manufacturing facility. However, investors should also consider SME IPO risk, negative operating cash flow, regulatory compliance risk, and customer concentration risk.
Finowings IPO Analysis
Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.
You must consult your financial advisor before making any financial decisions.
To Apply for the IPO, Click Here.
To Read the Prospectus of the Company, Click Here to Download the DRHP.
DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.
Other Related Blogs:-
OnEMI Technology Solutions IPO
